Behnoosh Tasharrofi - Department of Medical Genetics, Shahid Beheshti University of Medical Sciences Tehran, Iran

Introduction and aim: Breast cancer has caused many questions for researchers on the metastasis feature due to its diverse genetic and histologic molecular profiles and metastatic aspects of this cancer are one of the big challenges that every patient and doctor faces to find the best treatment. It is necessary to apply the drug development regarding this type of diversity so that both the patient will suffer the least physical and mental damage and incur the least cost as well as the doctor will be able to treat effectively and purposefully; this will not be possible except by examining the individual profile of each cancer.Method: Identification of driver mutations, for example, has also remained as the biggest challenge and Development of a bioinformatics tools can help solve this problem along with evaluating the pathway activation and dependency. The occurrence of the secondary resistance, such as ESR1 mutations following Endocrine Therapy raises further challenges. Ultra Deep sequencing and the examination of circulating tumor DNA can cause early detection of the genetic events, including the resistance and awareness of the combination therapy. The practical issues also create the main limitations for the personal medicine progress like the low incidence of most genomic alterations and the number of the screened.Conclusion: We discuss these limitations and their solutions, including increasing the number of the patients who are examined to detect their genomic variations, categorizing the genomic variations in different pathways and developing the experiments in the field of personalized medicine.

personalized medicine, Breast cancer, molecular profile, drug development